Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2015 Feb 25

PMID 25708799

Citations 12

Authors

Daniel G Stover

Nikhil Wagle

Affiliations

Soon will be listed here.

Abstract

Remarkable progress in sequencing technology over the past 20 years has made it possible to comprehensively profile tumors and identify clinically relevant genomic alterations. In breast cancer, the most common malignancy affecting women, we are now increasingly able to use this technology to help specify the use of therapies that target key molecular and genetic dependencies. Large sequencing studies have confirmed the role of well-known cancer-related genes and have also revealed numerous other genes that are recurrently mutated in breast cancer. This growing understanding of patient-to-patient variability at the genomic level in breast cancer is advancing our ability to direct the appropriate treatment to the appropriate patient at the appropriate time--a hallmark of "precision cancer medicine." This review focuses on the technological advances that have catalyzed these developments, the landscape of mutations in breast cancer, the clinical impact of genomic profiling, and the incorporation of genomic information into clinical care and clinical trials.

Citing Articles

A video intervention to improve patient understanding of tumor genomic testing in patients with cancer.

Veney D, Wei L, Toland A, Presley C, Hampel H, Padamsee T Cancer Med. 2024; 13(17):e70095.

PMID: 39258462 PMC: 11387988. DOI: 10.1002/cam4.70095.

Patient Graph Deep Learning to Predict Breast Cancer Molecular Subtype.

Furtney I, Bradley R, Kabuka M IEEE/ACM Trans Comput Biol Bioinform. 2023; 20(5):3117-3127.

PMID: 37379184 PMC: 10623656. DOI: 10.1109/TCBB.2023.3290394.

Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort.

Senter L, Veney D, Surplus T, Haynam M, Adams E, Hampel H JCO Oncol Pract. 2022; 19(1):e8-e14.

PMID: 36130146 PMC: 10166357. DOI: 10.1200/OP.22.00316.

Identification of Differentially Expressed Mirna by Next Generation Sequencing in Locally Advanced Breast Cancer Patients of South Indian Origin.

Tripathi S, Mathaiyan J, Kayal S, Ganesh R Asian Pac J Cancer Prev. 2022; 23(7):2255-2261.

PMID: 35901329 PMC: 9727336. DOI: 10.31557/APJCP.2022.23.7.2255.

Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions.

Zhang X, Yang H, Zhang R Biosci Rep. 2019; 39(9).

PMID: 31387972 PMC: 6732363. DOI: 10.1042/BSR20190230.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Pleasance E, Cheetham R, Stephens P, McBride D, Humphray S, Greenman C . A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009; 463(7278):191-6. PMC: 3145108. DOI: 10.1038/nature08658. View

Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

van de Vijver M, Peterse J, Mooi W, Wisman P, Lomans J, Dalesio O . Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988; 319(19):1239-45. DOI: 10.1056/NEJM198811103191902. View

Natrajan R, Mackay A, Lambros M, Weigelt B, Wilkerson P, Manie E . A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol. 2012; 227(1):29-41. PMC: 4976800. DOI: 10.1002/path.4003. View

Wagle N, Van Allen E, Treacy D, Frederick D, Cooper Z, Taylor-Weiner A . MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2013; 4(1):61-8. PMC: 3947296. DOI: 10.1158/2159-8290.CD-13-0631. View

Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N . Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014; 4(9):1014-21. PMC: 4155059. DOI: 10.1158/2159-8290.CD-14-0380. View

Lohr J, Adalsteinsson V, Cibulskis K, Choudhury A, Rosenberg M, Cruz-Gordillo P . Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014; 32(5):479-84. PMC: 4034575. DOI: 10.1038/nbt.2892. View

Lim W, Ong C, Tan J, Thike A, Ng C, Rajasegaran V . Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014; 46(8):877-80. DOI: 10.1038/ng.3037. View

10.

Van Allen E, Wagle N, Stojanov P, Perrin D, Cibulskis K, Marlow S . Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014; 20(6):682-8. PMC: 4048335. DOI: 10.1038/nm.3559. View

11.

Van Allen E, Wagle N, Levy M . Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013; 31(15):1825-33. PMC: 4878102. DOI: 10.1200/JCO.2013.48.7215. View

12.

Polyak K, Metzger Filho O . SnapShot: breast cancer. Cancer Cell. 2012; 22(4):562-562.e1. DOI: 10.1016/j.ccr.2012.06.021. View

13.

Smerage J, Barlow W, Hortobagyi G, Winer E, Leyland-Jones B, Srkalovic G . Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014; 32(31):3483-9. PMC: 4209100. DOI: 10.1200/JCO.2014.56.2561. View

14.

Toy W, Shen Y, Won H, Green B, Sakr R, Will M . ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013; 45(12):1439-45. PMC: 3903423. DOI: 10.1038/ng.2822. View

15.

Johnson D, Dahlman K, Knol J, Gilbert J, Puzanov I, Means-Powell J . Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014; 19(6):616-22. PMC: 4041676. DOI: 10.1634/theoncologist.2014-0011. View

16.

Wang Y, Waters J, Leung M, Unruh A, Roh W, Shi X . Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014; 512(7513):155-60. PMC: 4158312. DOI: 10.1038/nature13600. View

17.

Kan Z, Jaiswal B, Stinson J, Janakiraman V, Bhatt D, Stern H . Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-73. DOI: 10.1038/nature09208. View

18.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J . Tumour evolution inferred by single-cell sequencing. Nature. 2011; 472(7341):90-4. PMC: 4504184. DOI: 10.1038/nature09807. View

19.

Ingle J, Ahmann D, Green S, Edmonson J, Bisel H, Kvols L . Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981; 304(1):16-21. DOI: 10.1056/NEJM198101013040104. View

20.

Wagle N, Grabiner B, Van Allen E, Amin-Mansour A, Taylor-Weiner A, Rosenberg M . Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014; 371(15):1426-33. PMC: 4564868. DOI: 10.1056/NEJMoa1403352. View